- Clinical Trials
- November 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- April 2023
- 249 Pages
Global
From €3993EUR$4,200USD£3,354GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- July 2024
- 89 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- May 2022
- 42 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Book
- November 2013
- 982 Pages
- Book
- July 2020
- 416 Pages
- Book
- June 2018
- 816 Pages
- Book
- December 2023
- 496 Pages
- Book
- October 2010
- 760 Pages
- Book
- June 2020
- 372 Pages

Eclampsia is a serious complication of pregnancy that can occur in the late stages of pregnancy or during labor. It is characterized by seizures, high blood pressure, and protein in the urine. It is a leading cause of maternal and infant mortality and morbidity worldwide. It is estimated that eclampsia affects up to 10% of pregnant women in some countries.
Eclampsia is a major public health concern, and there is a need for improved diagnosis, treatment, and prevention. Treatment options include magnesium sulfate, antihypertensive medications, and delivery of the baby. Prevention strategies include early detection and management of high blood pressure during pregnancy, as well as improved nutrition and access to healthcare.
There are a number of companies in the eclampsia market, including Bayer, Pfizer, Merck, and Novartis. These companies are focused on developing new treatments and prevention strategies for eclampsia, as well as providing education and support to healthcare providers and patients. Show Less Read more